Glass Pharms has today announced a new supply deal set to see a new line of affordable, entirely UK-produced products enter the market.
Three new additions to the ‘EcoCann Access’ range, derived from Glass Pharms’ sustainably grown flower, will now be prescribed through CB1 Pharmacy and manufactured by Xeal Pharma.
The products are designed to provide a consistent and budget-friendly option for UK patients, with prices set at under £6 per gram, following a successful soft launch and several months of collaboration between the two companies.
Glass Pharms’ Head of External Relations, Mark Heley, told Business of Cannabis: “We had already established a successful partnership with CB1 Medical, which has already been prescribing Glass Pharms’ livery flower.
“We started thinking about how to meet our shared goals. CB1 is a fast-growing pharmacy with a mission to provide affordable access to medical cannabis in the UK, and that was a key consideration for us.”
He explained that, in conversations with patients and clinicians, ‘price point came up again and again’. As such, this new partnership is aimed at ‘finding a way to serve patients who need medical cannabis on a budget without compromising on quality’.
“We are listening to what patients and clinicians are asking for. And for a lot of them, it’s a reliable, affordable option that meets medical standards.”
The three new products are produced from lines that ‘include interesting cultivars’, but don’t meet the standards required for Glass Pharms’ core, more premium-priced product line in areas like stability or year-round availability.
According to Prohibition Partners’ latest data, over 500 separate products are now available to UK patients, a level of choice many new patients can find intimidating.
Unlike traditional medical cannabis offerings that often focus on specific cultivars, or strains with distinctive genetics, EcoCann Access is structured around broader cannabis phenotypes: Sativa, Indica and Balanced Hybrid.
These categories, while loosely defined, are commonly used by clinicians and patients to distinguish between ‘daytime’ and ‘nighttime’ effects.
“There’s only a portion of the market that’s hyper-focused on Californian genetics and cultivar names,” Heley explained. “A lot of people want good, consistent access. That’s what this is.”
Each product in the range will fall into one of the three phenotype categories, allowing prescribers to maintain continuity for patients even as specific cultivars change over time. Cultivar details will still be listed for transparency.
For daytime use, Chemstar (SA-T19-CHS) offers a Sativa Hybrid profile with 19% THC, while the balanced Hybrid option, Gelato 33 (BH-T15), features 15% THC and a terpene blend of Caryophyllene, Limonene, and Myrcene, while its nighttime cultivar, Motorbreath (IN–T19), offers robust Indica-leaning profile with 19% THC.
“We’ll always offer a daytime option, a nighttime option, and a day/night (balanced) option, that maps roughly onto the traditional cannabis phenotype model—Sativa, Indica, and Hybrid,” Heley continued.
Glass Pharms CEO James Duckenfield added that while phenotype classification is ‘not an exact science,’ it remains a ‘useful way of determining the general indication of a cannabis-based medicine.’
CB1 Medical, the launch partner for the range, operates a large NHS-linked practice in Leicester and brands itself as the ‘UK’s most affordable medical cannabis clinic.’ Founder Professor Rishabh Prasad said the partnership with Glass Pharms would improve both choice and accessibility for patients.
“I’ve seen Glass Pharms myself,” added CB1 Pharmacy’s Superintendent Pharmacist Irfan Abdulla. “They use the most robust processes to maintain the highest quality medicine.”
The new line also appeals to clinicians seeking prescribing stability in a market often plagued by supply inconsistency.
For Glass Pharms, the EcoCann Access project is a further extension of its UK-first ethos.
The company, which grows medical cannabis in a 2.4-hectare greenhouse in the West of England, became the first UK cultivator since medical cannabis was legalised in 2018 to deliver domestically grown product to patients last year.
The post Glass Pharms Signs Supply Agreement With CB1 Pharmacy Offering 3 New Affordable UK-Grown Strains appeared first on Business of Cannabis.
Continue reading...
Three new additions to the ‘EcoCann Access’ range, derived from Glass Pharms’ sustainably grown flower, will now be prescribed through CB1 Pharmacy and manufactured by Xeal Pharma.
The products are designed to provide a consistent and budget-friendly option for UK patients, with prices set at under £6 per gram, following a successful soft launch and several months of collaboration between the two companies.
Glass Pharms’ Head of External Relations, Mark Heley, told Business of Cannabis: “We had already established a successful partnership with CB1 Medical, which has already been prescribing Glass Pharms’ livery flower.
“We started thinking about how to meet our shared goals. CB1 is a fast-growing pharmacy with a mission to provide affordable access to medical cannabis in the UK, and that was a key consideration for us.”
He explained that, in conversations with patients and clinicians, ‘price point came up again and again’. As such, this new partnership is aimed at ‘finding a way to serve patients who need medical cannabis on a budget without compromising on quality’.
“We are listening to what patients and clinicians are asking for. And for a lot of them, it’s a reliable, affordable option that meets medical standards.”
The three new products are produced from lines that ‘include interesting cultivars’, but don’t meet the standards required for Glass Pharms’ core, more premium-priced product line in areas like stability or year-round availability.
Simplifying product choice
According to Prohibition Partners’ latest data, over 500 separate products are now available to UK patients, a level of choice many new patients can find intimidating.
Unlike traditional medical cannabis offerings that often focus on specific cultivars, or strains with distinctive genetics, EcoCann Access is structured around broader cannabis phenotypes: Sativa, Indica and Balanced Hybrid.
These categories, while loosely defined, are commonly used by clinicians and patients to distinguish between ‘daytime’ and ‘nighttime’ effects.
“There’s only a portion of the market that’s hyper-focused on Californian genetics and cultivar names,” Heley explained. “A lot of people want good, consistent access. That’s what this is.”
Each product in the range will fall into one of the three phenotype categories, allowing prescribers to maintain continuity for patients even as specific cultivars change over time. Cultivar details will still be listed for transparency.
For daytime use, Chemstar (SA-T19-CHS) offers a Sativa Hybrid profile with 19% THC, while the balanced Hybrid option, Gelato 33 (BH-T15), features 15% THC and a terpene blend of Caryophyllene, Limonene, and Myrcene, while its nighttime cultivar, Motorbreath (IN–T19), offers robust Indica-leaning profile with 19% THC.
“We’ll always offer a daytime option, a nighttime option, and a day/night (balanced) option, that maps roughly onto the traditional cannabis phenotype model—Sativa, Indica, and Hybrid,” Heley continued.
Glass Pharms CEO James Duckenfield added that while phenotype classification is ‘not an exact science,’ it remains a ‘useful way of determining the general indication of a cannabis-based medicine.’
Rooted in the UK
CB1 Medical, the launch partner for the range, operates a large NHS-linked practice in Leicester and brands itself as the ‘UK’s most affordable medical cannabis clinic.’ Founder Professor Rishabh Prasad said the partnership with Glass Pharms would improve both choice and accessibility for patients.
“I’ve seen Glass Pharms myself,” added CB1 Pharmacy’s Superintendent Pharmacist Irfan Abdulla. “They use the most robust processes to maintain the highest quality medicine.”
The new line also appeals to clinicians seeking prescribing stability in a market often plagued by supply inconsistency.
For Glass Pharms, the EcoCann Access project is a further extension of its UK-first ethos.
The company, which grows medical cannabis in a 2.4-hectare greenhouse in the West of England, became the first UK cultivator since medical cannabis was legalised in 2018 to deliver domestically grown product to patients last year.
The post Glass Pharms Signs Supply Agreement With CB1 Pharmacy Offering 3 New Affordable UK-Grown Strains appeared first on Business of Cannabis.
Continue reading...
